BR112022021420A2 - Tratamento de condições associadas a hormônios tireoidianos - Google Patents

Tratamento de condições associadas a hormônios tireoidianos

Info

Publication number
BR112022021420A2
BR112022021420A2 BR112022021420A BR112022021420A BR112022021420A2 BR 112022021420 A2 BR112022021420 A2 BR 112022021420A2 BR 112022021420 A BR112022021420 A BR 112022021420A BR 112022021420 A BR112022021420 A BR 112022021420A BR 112022021420 A2 BR112022021420 A2 BR 112022021420A2
Authority
BR
Brazil
Prior art keywords
conditions associated
treatment
thyroid hormones
compositions
treating
Prior art date
Application number
BR112022021420A
Other languages
English (en)
Portuguese (pt)
Inventor
O Scott Linzy Iii
Original Assignee
O Scott Linzy Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O Scott Linzy Iii filed Critical O Scott Linzy Iii
Publication of BR112022021420A2 publication Critical patent/BR112022021420A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022021420A 2020-04-22 2021-04-22 Tratamento de condições associadas a hormônios tireoidianos BR112022021420A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063013960P 2020-04-22 2020-04-22
US202063088523P 2020-10-07 2020-10-07
US202163135118P 2021-01-08 2021-01-08
PCT/US2021/028675 WO2021216896A1 (en) 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone

Publications (1)

Publication Number Publication Date
BR112022021420A2 true BR112022021420A2 (pt) 2022-12-27

Family

ID=78270024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021420A BR112022021420A2 (pt) 2020-04-22 2021-04-22 Tratamento de condições associadas a hormônios tireoidianos

Country Status (12)

Country Link
US (1) US20230149410A1 (enExample)
EP (1) EP4138809A4 (enExample)
JP (1) JP2023522956A (enExample)
KR (1) KR20230015906A (enExample)
CN (1) CN115916177A (enExample)
AU (1) AU2021260956A1 (enExample)
BR (1) BR112022021420A2 (enExample)
CA (1) CA3175608A1 (enExample)
IL (1) IL297453A (enExample)
MX (1) MX2022013140A (enExample)
PH (1) PH12022553118A1 (enExample)
WO (1) WO2021216896A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522112A (ja) * 2022-07-11 2025-07-10 プリズム・エルエルシー アラン・ハーンドン・ダドリー症候群を治療するための方法
CA3261855A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC METHODS AND FORMULATIONS OF GENE THERAPY, AND OF COMBINATION OF GENE THERAPY WITH DITPA THERAPY, FOR ALLAN-HERNDON-DUDLEY SYNDROME
US20240350591A1 (en) * 2023-04-12 2024-10-24 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation
CN121910745B (zh) * 2026-03-23 2026-05-26 暨南大学 N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1243101A (en) * 1999-10-28 2001-05-08 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
IT1320776B1 (it) * 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
HRP20160406T1 (hr) * 2009-07-10 2016-05-20 Linzy O. Scott Iii Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
WO2012171065A1 (en) * 2011-06-17 2012-12-20 Esra Ogru Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa).
US10640748B2 (en) * 2014-12-24 2020-05-05 Neuorphan Pty Ltd Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease

Also Published As

Publication number Publication date
EP4138809A1 (en) 2023-03-01
MX2022013140A (es) 2022-11-16
EP4138809A4 (en) 2024-05-01
CA3175608A1 (en) 2021-10-28
CN115916177A (zh) 2023-04-04
US20230149410A1 (en) 2023-05-18
KR20230015906A (ko) 2023-01-31
AU2021260956A1 (en) 2022-11-17
IL297453A (en) 2022-12-01
PH12022553118A1 (en) 2023-04-03
WO2021216896A1 (en) 2021-10-28
JP2023522956A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
PH12022553118A1 (en) Treatment of conditions associated with thyroid hormone
MX9205681A (es) Aminometil-cromanos, procedimiento para su fabricacion y medicamento que los contiene.
Sojka et al. Escherichia coli serotypes associated with certain pig diseases
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
DK0798968T3 (da) Middel til at forbedre produktionen og avlen af produktionsdyr inden for fjerkræsindustrien
Zoratto et al. Neonatal tryptophan depletion and corticosterone supplementation modify emotional responses in adult male mice
PH12017500135B1 (en) Treatment and prevention of the common cold using povidone-iodine
ES2103733T3 (es) Procedimiento para combatir el piojo de los peces.
BR112022016304A2 (pt) Métodos de prognóstico terapêutico.
ES2063747T3 (es) Nuevos benzotiofenos que tienen actividad antialergica, asi como nuevos benzotiofenos y otros benzotiofenos seleccionados que tienen actividad para el tratamiento del sindrome de malestar respiratorio agudo.
BR8707751A (pt) Aperfeicoamento em aparelhos para produzir material para haste de filtro a partir de uma estopa fibrosa e elemento de conduto
Pal et al. A comparative study between oral pregabalin and gabapentin in prolongation of postoperative pain relief after spinal anesthesia
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
DK162048C (da) 4-oxothiazolidin-2-yliden-acetamidderivater, fremgangsmaade til deres fremstilling samt deres anvendelse
Firacative et al. Circulation of Streptococcus pneumoniae clone Colombia5 ST289 in nine Latin American countries
IT1247144B (it) Composizioni stabilizzanti per polimeri organici
BR112021024927A2 (pt) Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metil-ciclo-hexanocarbonil)-amino]-acético para tratamento de tosse crônica
CR20220247A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
BR9915899A (pt) Composto, composição farmacêutica e método para tratar ou inibir distúrbios associados com contração do músculo liso.
NZ788497A (en) Use of reboxetine to treat nervous system disorders
KIM A Study Comparing SPECT with MRI in Patients with Traumatic Brain Injury
LI Clinical effect of quadruple scheme combined with bismuth in the treatment of patients with helicobacter pylori
ZHANG et al. Effects of Two Different Splints on Treatment of Temporomandibular Joint Disorders.
Gimenez-Mila Pruritus: case report
CHEN A Clinical Study of Shexiang Hemostasis-removing Plaster

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: CABE SER ANULADO O DESPACHO PUBLICADO NA RPI 2876 DE 18/02/2026, ITEM 8.6, REFERENTE AO ARQUIVAMENTO, UMA VEZ QUE O RECOLHIMENTO DA 5O ANUIDADE FOI EFETUADO EM 21/07/2025, ATRAVES DA GRU 800250287493.